Fumitaka Mizoguchi

Fumitaka Mizoguchi

Auto-generated profile, based on publicly available information

Fumitaka Mizoguchi

Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2017 in Nature
Verified
Journal Article
Closed access
PDF file
DRDeepak A. Rao
Deepak A. Rao
MGMichael F. Gurish
Michael F. Gurish
JMJennifer L. Marshall
Jennifer L. Marshall
KSKamil Slowikowski
Kamil Slowikowski
CFChamith Y. Fonseka
Chamith Y. Fonseka
MBMichael B. Brenner
Michael B. Brenner

23 February 2018 in Nature Communications
Verified
Journal Article
Open access
PDF file
FMFumitaka Mizoguchi
Fumitaka Mizoguchi
KSKamil Slowikowski
Kamil Slowikowski
KWKevin Wei
Kevin Wei
JMJennifer L. Marshall
Jennifer L. Marshall
DRDeepak A. Rao
Deepak A. Rao
MBMichael B. Brenner
Michael B. Brenner
Fibroblasts regulate tissue homeostasis, coordinate inflammatory responses, and mediate tissue damage. In rheumatoid arthritis (RA), synovial fibroblasts maintain chronic inflammation which leads to joint destruction. Little is known about fibroblast heterogeneity or if aberrations in fibroblast subsets relate to pathology. Here, we show functional and transcriptional differences between fibroblast subsets from human synovial tissues using bulk transcriptomics of targeted subpopulations and single-cell transcriptomics. We identify seven fibroblast subsets with distinct surface protein phenotypes, and collapse them into three subsets by integrating transcriptomic data. One fibroblast subset, characterized by the expression of proteins podoplanin, THY1 membrane glycoprotein and cadherin-11, but lacking CD34, is threefold expanded in patients with RA relative to patients with osteoarthritis. These fibroblasts localize to the perivascular zone in inflamed synovium, secrete proinflammatory cytokines, are proliferative, and have an in vitro phenotype characteristic of invasive cells. Our strategy may be used as a template to identify pathogenic stromal cellular subsets in other complex diseases.

1 February 2017 in Immunity
Verified
Journal Article
Closed access
HNHung N. Nguyen
Hung N. Nguyen
ENErika H. Noss
Erika H. Noss
FMFumitaka Mizoguchi
Fumitaka Mizoguchi
CHChristine Huppertz
Christine Huppertz
KWKevin S. Wei
Kevin S. Wei
MBMichael B. Brenner
Michael B. Brenner

28 December 2009 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
FMFumitaka Mizoguchi
Fumitaka Mizoguchi
YIYayoi Izu
Yayoi Izu
THTadayoshi Hayata
Tadayoshi Hayata
HHHiroaki Hemmi
Hiroaki Hemmi
KNKazuhisa Nakashima
Kazuhisa Nakashima
MNMasaki Noda
Masaki Noda

1 October 2013 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
FMFumitaka Mizoguchi
Fumitaka Mizoguchi
YMYousuke Murakami
Yousuke Murakami
TSTetsuya Saito
Tetsuya Saito
NMNobuyuki Miyasaka
Nobuyuki Miyasaka
HKHitoshi Kohsaka
Hitoshi Kohsaka
Introduction: Increased activity of osteoclasts is responsible for bone loss and joint destruction in rheumatoid arthritis. For osteoclast development and bone resorption activity, cytoskeletal organization must be properly regulated. MicroRNAs (miRNAs) are endogenous small noncoding RNAs that suppress expression of their target genes. This study was conducted to identify crucial miRNAs to control osteoclasts. Methods: miRNA expression in the bone marrow-derived macrophages (BMM) with or without receptor activator of nuclear factor κB ligand (RANKL) stimulation was analyzed by miRNA array. To examine the role of specific miRNAs in osteoclast formation, bone resorption activity and actin ring formation, the BMM were retrovirally transduced with miRNA antagomirs. To confirm whether the suppressive effects on osteoclastogenesis by miR-31 inhibition were mediated by targeting RhoA, osteoclast formation was analyzed in the presence of the RhoA inhibitor, exoenzyme C3. Results: miR-31 was identified as one of the highly upregulated miRNAs during osteoclast development under RANKL stimulation. Inhibition of miR-31 by specific antagomirs suppressed the RANKL-induced formation of osteoclasts and bone resorption. Phalloidin staining of osteoclasts revealed that actin ring formation at the cell periphery was severely impaired by miR-31 inhibition, and clusters of small ringed podosomes were observed instead. In these osteoclasts, expression of RhoA, one of the miR-31 target genes, was upregulated by miR-31 inhibition in spite of the impaired osteoclastogenesis. Treatment with the RhoA inhibitor, exoenzyme C3, rescued the osteoclastogenesis impaired by miR-31 inhibition. Conclusions: miR-31 controls cytoskeleton organization in osteoclasts for optimal bone resorption activity by regulating the expression of RhoA.

11 July 2018 in Arthritis Research & Therapy
Verified
Journal Article
Open access
PDF file
ANAccelerating Medicines Partnership RA/SLE Network
Accelerating Medicines Partnership RA/SLE Network
LDLaura Donlin
Laura Donlin
DRDeepak A. Rao
Deepak A. Rao
KWKevin Wei
Kevin Wei
KSKamil Slowikowski
Kamil Slowikowski
JAJennifer H. Anolik
Jennifer H. Anolik
Detailed molecular analyses of cells from rheumatoid arthritis (RA) synovium hold promise in identifying cellular phenotypes that drive tissue pathology and joint damage. The Accelerating Medicines Partnership RA/SLE Network aims to deconstruct autoimmune pathology by examining cells within target tissues through multiple high-dimensional assays. Robust standardized protocols need to be developed before cellular phenotypes at a single cell level can be effectively compared across patient samples. Multiple clinical sites collected cryopreserved synovial tissue fragments from arthroplasty and synovial biopsy in a 10% DMSO solution. Mechanical and enzymatic dissociation parameters were optimized for viable cell extraction and surface protein preservation for cell sorting and mass cytometry, as well as for reproducibility in RNA sequencing (RNA-seq). Cryopreserved synovial samples were collectively analyzed at a central processing site by a custom-designed and validated 35-marker mass cytometry panel. In parallel, each sample was flow sorted into fibroblast, T-cell, B-cell, and macrophage suspensions for bulk population RNA-seq and plate-based single-cell CEL-Seq2 RNA-seq. Upon dissociation, cryopreserved synovial tissue fragments yielded a high frequency of viable cells, comparable to samples undergoing immediate processing. Optimization of synovial tissue dissociation across six clinical collection sites with ~ 30 arthroplasty and ~ 20 biopsy samples yielded a consensus digestion protocol using 100 μg/ml of Liberase™ TL enzyme preparation. This protocol yielded immune and stromal cell lineages with preserved surface markers and minimized variability across replicate RNA-seq transcriptomes. Mass cytometry analysis of cells from cryopreserved synovium distinguished diverse fibroblast phenotypes, distinct populations of memory B cells and antibody-secreting cells, and multiple CD4+ and CD8+ T-cell activation states. Bulk RNA-seq of sorted cell populations demonstrated robust separation of synovial lymphocytes, fibroblasts, and macrophages. Single-cell RNA-seq produced transcriptomes of over 1000 genes/cell, including transcripts encoding characteristic lineage markers identified. We have established a robust protocol to acquire viable cells from cryopreserved synovial tissue with intact transcriptomes and cell surface phenotypes. A centralized pipeline to generate multiple high-dimensional analyses of synovial tissue samples collected across a collaborative network was developed. Integrated analysis of such datasets from large patient cohorts may help define molecular heterogeneity within RA pathology and identify new therapeutic targets and biomarkers.